PSQI score meaning is simple: higher numbers mean more reported sleep problems over the past month. The Pittsburgh Sleep Quality Index, or PSQI, runs from 0 to 21. A score above 5 flagged poor sleep in the original study. It helps describe the problem; it doesn't diagnose its cause or pick a treatment.
PSQI score meaning: the 0–21 range
The global score means the total. It adds seven component scores, meaning seven parts of the sleep picture. Each part receives 0 to 3 points, with higher scores reflecting more difficulty.
The score comes from 19 answers supplied by the person completing the form. Those answers are grouped and scored before the seven parts are added.
The points aren't hours of sleep or a percentage. A higher total can come from several different patterns, so the component scores matter alongside it.
The University of Pittsburgh's current PSQI guidance keeps the recall period, the time being described, at one month. Its guidance supports that monthly window. Questions rewritten to cover just last night or the past week no longer have the same evidence behind them.
The seven components behind the total
The components cover both nighttime sleep and how sleep affects the day.
| Component | What it describes |
|---|---|
| Subjective sleep quality | How someone judges their sleep overall |
| Sleep latency | How long falling asleep takes |
| Sleep duration | The amount of sleep reported |
| Habitual sleep efficiency | The share of time in bed spent asleep |
| Sleep disturbances | Problems that interrupt sleep |
| Sleeping medication use | How often sleep medicines are used |
| Daytime dysfunction | Trouble staying awake and maintaining enthusiasm during the day |
Pittsburgh's scoring guidance explains how the answers become component scores. Simply adding the raw answers isn't the scoring method.
That breakdown matters when someone asks about DSIP, delta sleep-inducing peptide, a short chain of protein building blocks studied in sleep research. A provider needs a defined complaint: difficulty falling asleep, interrupted sleep and daytime dozing raise different questions. The DSIP benefits guide covers the treatment evidence separately.
What the original cutoff actually found
Buysse and colleagues' 1989 validation study in Psychiatry Research tested whether PSQI scores distinguished groups already assessed clinically. The full report analyzed 148 adults:
| Group in the full report | Participants |
|---|---|
| Healthy adults without sleep complaints | 52 |
| Patients with major depression | 34 |
| Patients assessed for sleep disorders | 62 |
In that study, a global score greater than 5 flagged roughly 9 in 10 poor sleepers. Sensitivity, the share of poor sleepers correctly flagged, was 89.6%.
Specificity, the share of good sleepers correctly classified, was 86.5%. That also means some good sleepers crossed the cutoff and some poor sleepers did not.
Those figures describe performance in that sample. They aren't the probability that a particular person has insomnia, ongoing difficulty falling or staying asleep. The cutoff was selected after examining the study data, which also matters when applying it elsewhere.
A sleep-quality score cannot measure everything
PSQI is subjective, meaning it relies on the person's report. It doesn't record brain waves, count minutes of deep sleep or measure breathing interruptions.
A low score doesn't settle a concern about sleep apnea, repeated breathing interruptions during sleep. The DSIP and sleep apnea guide explains why breathing needs its own assessment.
For a sleep-related DSIP request, the measure needs to match the complaint. A questionnaire about perceived sleep and a test of overnight breathing answer different questions. Improvement in one cannot stand in for evidence about the other.
How much PSQI change is meaningful?
A falling score means fewer reported problems. How much change someone notices depends on the condition, starting score and setting.
Researchers call a change patients consider beneficial a minimal clinically important difference. It isn't automatically the same number for every group.
For example, Longo and colleagues' 2021 study in the International Journal of Environmental Research and Public Health followed 50 patients after shoulder-tendon repair. The authors selected a 4.4-point improvement as meaningful at six months. That estimate belongs to those surgical patients and that follow-up period; it isn't a DSIP target.
As of November 12, 2026, the day this article was written, a review published August 18 in Frontiers in Psychology, corrected August 26, adds context about translated scores. It examined Arabic-language sleep measures, including nine PSQI validation studies, and found limited evidence about detecting meaningful change over time. Those findings concern the versions and populations reviewed, rather than establishing a universal change threshold.
What a useful follow-up would record
A useful comparison keeps the questionnaire version and its month-long window consistent. The total, individual components, current medicines and changes in daily functioning give a provider more context than a score alone.
A lower score after starting something doesn't establish that it caused the change. Other treatment, changed schedules and ordinary variation can affect the same period.
The 1992 DSIP insomnia trial illustrates why sleep recordings and people's sleep ratings need separate attention. Its findings don't establish that DSIP improves PSQI scores. A provider considering DSIP needs an appropriate measure and a clear understanding of what improvement would mean for that person's complaint.
What the score means for a prescription
A PSQI result can inform a conversation, but it doesn't select a medication.
As of November 12, 2026, the day this article was written, HHS, the Department of Health and Human Services, has published an October 30 notice announcing a nonbinding draft peptide-compounding policy. DSIP is absent from its six-peptide Appendix A; the HHS policy explainer covers its ten conditions.
DSIP prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that compounded medicines do not undergo its review for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful starting point is a description of the sleep problem, with a score that helps explain it.





